EPS for Halozyme Therapeutics, Inc. (HALO) Expected At $-0.21; Ing Risk Managed Natural Resources Fund (IRR)’s Sentiment Is 1.1

April 17, 2018 - By Michael Collier

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Logo

Analysts expect Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report $-0.21 EPS on May, 10 after the close.They anticipate $0.05 EPS change or 19.23% from last quarter’s $-0.26 EPS. After having $0.85 EPS previously, Halozyme Therapeutics, Inc.’s analysts see -124.71% EPS growth. The stock increased 2.70% or $0.52 during the last trading session, reaching $19.79. About 345,868 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.10% since April 17, 2017 and is uptrending. It has outperformed by 20.55% the S&P500.

Ing Risk Managed Natural Resources Fund (IRR) investors sentiment increased to 1.1 in 2017 Q4. It’s up 0.27, from 0.83 in 2017Q3. The ratio is positive, as 11 investment managers increased or opened new positions, while 10 cut down and sold their holdings in Ing Risk Managed Natural Resources Fund. The investment managers in our database now possess: 4.01 million shares, up from 3.83 million shares in 2017Q3. Also, the number of investment managers holding Ing Risk Managed Natural Resources Fund in top ten positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 7 Increased: 6 New Position: 5.

The stock increased 0.16% or $0.01 during the last trading session, reaching $6.14. About 85,080 shares traded or 40.84% up from the average. Voya Natural Resources Equity Income Fund (IRR) has declined 3.23% since April 17, 2017 and is downtrending. It has underperformed by 14.78% the S&P500.

Advisors Asset Management Inc. holds 0.11% of its portfolio in Voya Natural Resources Equity Income Fund for 1.05 million shares. Guggenheim Capital Llc owns 368,176 shares or 0.01% of their US portfolio. Moreover, Weiss Asset Management Lp has 0.01% invested in the company for 11,447 shares. The Minnesota-based Ameriprise Financial Inc has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 88,826 shares.

Among 10 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Halozyme Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. On Wednesday, August 9 the stock rating was maintained by Piper Jaffray with “Buy”. The rating was maintained by Canaccord Genuity on Wednesday, November 8 with “Buy”. The rating was maintained by Canaccord Genuity on Wednesday, July 26 with “Buy”. The company was downgraded on Wednesday, November 22 by Barclays Capital. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Buy” rating by Citigroup on Wednesday, November 18. As per Friday, September 15, the company rating was maintained by BMO Capital Markets. Barclays Capital initiated the shares of HALO in report on Tuesday, September 22 with “Overweight” rating. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Buy” rating given on Thursday, November 3 by Deutsche Bank. The company was maintained on Wednesday, February 24 by Barclays Capital. The firm earned “Overweight” rating on Wednesday, February 21 by JP Morgan.

Investors sentiment increased to 1.66 in Q4 2017. Its up 0.40, from 1.26 in 2017Q3. It increased, as 13 investors sold Halozyme Therapeutics, Inc. shares while 45 reduced holdings. 39 funds opened positions while 57 raised stakes. 118.31 million shares or 0.18% less from 118.53 million shares in 2017Q3 were reported. First Tru Advsrs Ltd Partnership has 78,251 shares. Jane Street Group Ltd Liability Corporation accumulated 27,476 shares. Los Angeles Capital Equity has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Barclays Public Ltd Co accumulated 0% or 63,403 shares. 2,550 are held by Natl Bank Of Montreal Can. Atlantic Tru Gru Llc, Georgia-based fund reported 22,801 shares. Alliancebernstein Limited Partnership has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 271,654 shares. 4,757 were reported by First Quadrant Lp Ca. Art Limited Liability Com, New York-based fund reported 199,021 shares. Wellington Mngmt Gru Llp stated it has 118,376 shares or 0% of all its holdings. Bb Biotech Ag owns 8.52M shares for 4.86% of their portfolio. Clarivest Asset Mngmt invested in 0.02% or 50,186 shares. Royal Commercial Bank Of Canada accumulated 3,441 shares or 0% of the stock. Qs Invsts Ltd, a New York-based fund reported 102,706 shares. Moreover, Weiss Asset Mngmt L P has 0.04% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: